Literature DB >> 3109860

Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease.

M S Flam, M J John, P A Mowry, L J Lovalvo, L D Ramalho, J Wade.   

Abstract

Thirty patients with epidermoid carcinoma of the anus, ranging in age from 40 to 89 years, were treated with combined chemotherapy (CT) and radiation therapy (RT) in lieu of abdominoperineal resection. Two courses of 5-FU (1000 mg/m2/day X four days) by continuous infusion and mitomycin-C (10-15 mg/m2 IV bolus on day 1 of each course) were given 3 to 4 weeks apart simultaneously, with whole pelvis RT to 4140 to 4500 cGy. Twenty-one of 28 patients had T3-T4 primaries and ten had positive nodes (N1). Two of the 30 patients were treated for local recurrence following surgical excision and one was treated immediately after local excision. Twenty-six of the 30 patients attained biopsy-confirmed complete remission. Four of the 30 patients demonstrated residual disease at completion of therapy but all subsequently achieved complete remission with additional nonsurgical treatment. One patient, initially treated for local recurrence following excision failed locally at four years and was salvaged with chemotherapy followed by abdominoperineal resection. No patient has experienced distant failure. Twenty-seven of 30 patients were alive and disease free after 9 to 76 months of follow-up and three died, disease-free, of unrelated causes. Acute toxicities were mild and did not necessitate interruption of treatment. A brisk perineal reaction and diarrhea were noted in all patients. Late complications were unusual. All patients were treated in a community-based, private practice setting. The authors conclude that combined CT-RT, as employed herein, represents a first-line curative treatment for the majority of patients with epidermoid anal carcinoma. For patients who demonstrate residual disease following this therapy, salvage regimens such as 5-FU infusion and cisplatin, or sequential MTX-5-FU-Leucovorin with additional synchronous RT should be employed before resorting to radical surgery.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109860     DOI: 10.1007/bf02554777

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

Review 1.  Advances in the Management of Anal Cancer.

Authors:  Diana R Julie; Karyn A Goodman
Journal:  Curr Oncol Rep       Date:  2016-03       Impact factor: 5.075

2.  Combined chemoradiation therapy for anal cancer. A report of 56 cases.

Authors:  R Doci; R Zucali; L Bombelli; F Montalto; G Lamonica
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

Review 3.  Squamous cell cancer of the rectum.

Authors:  Tara Dyson; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

4.  Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.

Authors:  W E Longo; A M Vernava; T P Wade; M A Coplin; K S Virgo; F E Johnson
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

5.  Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus.

Authors:  J D Ellenhorn; W E Enker; S H Quan
Journal:  Ann Surg Oncol       Date:  1994-03       Impact factor: 5.344

6.  Premalignant lesions of the anal canal and squamous cell carcinoma of the anal canal.

Authors:  Juan Lucas Poggio
Journal:  Clin Colon Rectal Surg       Date:  2011-09

7.  Anal cancer: the case for earlier diagnosis.

Authors:  A T Edwards; L C Morus; M E Foster; G H Griffith
Journal:  J R Soc Med       Date:  1991-07       Impact factor: 18.000

8.  Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.

Authors:  N Charnley; A Choudhury; P Chesser; R A Cooper; D Sebag-Montefiore
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

9.  Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.

Authors:  Byoung Chul Cho; Joong Bae Ahn; Jinsil Seong; Jae Kyung Roh; Joo Hang Kim; Hyun Cheol Chung; Joo Hyuk Sohn; Nam Kyu Kim
Journal:  BMC Cancer       Date:  2008-01-15       Impact factor: 4.430

10.  Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy.

Authors:  L Chauveinc; X Buthaud; M C Falcou; V Mosseri; A De la Rochefordière; J Y Pierga; J Girodet; R J Salmon
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.